Derangement of the T-cell repertoire in patients with B-cell non-Hodgkin's lymphoma

European Journal of Haematology

Volumn 94, Issue 4, 2015, Pages 298-309

  Fozza, Claudio ^a   Corda, Giovanna ^a   Virdis, Patrizia ^a   Contini, Salvatore ^a   Barraqueddu, Francesca ^a   Galleu, Antonio ^a   Isoni, Antonella ^a   Cossu, Antonella ^a   Dore, Fausto ^a   Careddu, Maria G ^a   Bonfigli, Silvana ^a   Giannico, Barbara ^a   Longinotti, Maurizio ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Flow cytometry; Non Hodgkin's lymphoma; Regulatory T cells; Spectratyping; T cell receptor repertoire; Third complementarity determining region

Indexed keywords

T LYMPHOCYTE RECEPTOR; ANTINEOPLASTIC AGENT; COMPLEMENTARITY DETERMINING REGION; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; LARGE CELL LYMPHOMA; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; BONE MARROW; CANCER STAGING; CLONAL EVOLUTION; COMPLEMENTARITY DETERMINING REGION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOCYTE COUNT; LYMPHOMA, B-CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CLONAL EVOLUTION; COMPLEMENTARITY DETERMINING REGIONS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOCYTE COUNT; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTE SUBSETS;

EID: 84925446528     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12417     Document Type: Article

References (36)

1. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012;380:848-57.
2. Miles JJ, Douek DC, Price DA. Bias in the αβ T-cell repertoire: implications for disease pathogenesis and vaccination. Immunol Cell Biol 2011;89:375-87.
3. Langerak AW, van Den Beemd R, Wolvers-Tettero IL, Boor PP, van Lochem EG, Hooijkaas H, van Dongen JJ. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood 2001;98:165-73.
4. Gorski J, Yassai M, Zhu X, Kissela B, Keever C, Flomenberg N. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J Immunol 1994;152:5109-19.
5. Fozza C, Longinotti M. T-cell receptor repertoire usage in hematologic malignancies. Crit Rev Oncol Hematol 2013;86:201-11.
6. Galleu A, Fozza C, Simula MP, et al. CD4(+) and CD8(+) T-cell skewness in classic Kaposi sarcoma. Neoplasia 2012;14:487-94.
7. Christopoulos P, Follo M, Fisch P, Veelken H. The peripheral helper T-cell repertoire in untreated indolent B-cell lymphomas: evidence for antigen-driven lymphomagenesis. Leukemia 2008;22:1952-4.
8. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010;10:490-500.
9. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+ CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006;107:3639-46.
10. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+ CD25 T cells. Blood 2007;110:2537-44.
11. Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN, Vickers MA. Local and systemic induction of CD4+ CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008;111:5359-70.
12. Han Y, Wu J, Bi L, Gao S, Yin L, Jiang L, Chen C, Yu K, Zhang S. Malignant B cells induce the conversion of CD4+ CD25- T cells to regulatory T cells in B-cell non-Hodgkin lymphoma. PLoS ONE 2011;6:e28649.
13. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
14. Fozza C, Longu F, Contini S, Galleu A, Virdis P, Bonfigli S, Murineddu M, Gabbas A, Longinotti M. Patients with early-stage myelodysplastic syndromes show increased frequency of CD4+ CD25+ CD127(low) regulatory T cells. Acta Haematol 2012;128:178-82.
15. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
16. Chen X, Barfield R, Benaim E, et al. Prediction of T-cell reconstitution by assessment of T-cell receptor excision circle before allogeneic hematopoietic stem cell transplantation in pediatric patients. Blood 2005;105:886-93.
17. Fozza C, Contini S, Galleu A, Simula MP, Virdis P, Bonfigli S, Longinotti M. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol 2009;37:947-55.
18. Fozza C, Longinotti M. The role of T-cells in the pathogenesis of myelodysplastic syndromes: passengers and drivers. Leuk Res 2013;37:201-3.
19. Fozza C, Longinotti M. Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes? Eur J Haematol 2012;88:380-7.
20. Janowska-Wieczorek A, Andrews EJ, Khaliq A, Pilarski LM. Deficiency of mature B and T lymphocyte subsets in the blood of non-Hodgkin lymphoma patients. Am J Hematol 1987;26:125-34.
21. Anichini A, Mortarini R, Romagnoli L, Baldassari P, Cabras A, Carlo-Stella C, Gianni AM, Di Nicola M. Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with gammac cytokines. Blood 2006;107:602-9.
22. Laurent C, Müller S, Do C, et al. Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood 2011;118:5371-9.
23. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390-8.
24. Alvaro T, Lejeune M, Salvadó MT, Lopez C, Jaén J, Bosch R, Pons LE. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006;24:5350-7.
25. Bagot M, Echchakir H, Mami-Chouaib F, Delfau-Larue MH, Charue D, Bernheim A, Chouaib S, Boumsell L, Bensussan A. Isolation of tumor-specific cytotoxic CD4+ and CD4+ CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 1998;91:4331-41.
26. Yawalkar N, Ferenczi K, Jones DA, Yamanaka K, Suh KY, Sadat S, Kupper TS. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003;102:4059-66.
27. Yamanaka K, Fuhlbrigge RC, Mizutani H, Kupper TS. Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell lymphoma. Arch Dermatol Res 2010;302:453-9.
28. Araki A, Taniguchi M, Mikata A. T cell receptor V beta repertoires of angioimmunoblastic lymphadenopathy-like T cell lymphoma. Leuk Lymphoma 1994;16:135-40.
29. Tan H, Ye J, Luo X, Yin Q, Yang L, Li Y. Clonal expanded TRA and TRB subfamily T cells in peripheral blood from patients with diffuse large B-cell lymphoma. Hematology 2010;15:81-7.
30. Yang ZZ, Grote DM, Ziesmer SC, Xiu B, Yates NR, Secreto FJ, Hodge LS, Witzig TE, Novak AJ, Ansell SM. Soluble and membrane-bound TGF-β-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma. PLoS ONE 2013;8:e59456.
31. Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 2012;11:790-811.
32. Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol 2010;85:896-9.
33. Porrata LF, Rsitow K, Inwards DJ, et al. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia 2010;24:1343-9.
34. Caocci G, La Nasa G, Efficace F. Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes. Expert Rev Hematol 2009;2:69-80.
35. Smith SK, Mayer DK, Zimmerman S, Williams CS, Benecha H, Ganz PA, Edwards LJ, Abernethy AP. Quality of life among long-term survivors of non-Hodgkin lymphoma: a follow-up study. J Clin Oncol 2013;31:272-9.
36. La Nasa G, Caocci G, Efficace F, et al. Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood 2013;122:2262-70.